Skip to main navigation Skip to search Skip to main content

Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program

  • Christiane Stern
  • , Véronique Loustaud-Ratti
  • , Cihan Yurdaydin
  • , Giuseppina Brancaccio
  • , Mathias Jachs
  • , Thomas Reiberger
  • , Edouard Bardou-Jacquet
  • , Sophie Metivier
  • , Laurent Alric
  • , Lea Colombain
  • , Magdalena Meszaros
  • , Philippe Mathurin
  • , David Yardeni
  • , Ohad Etzion
  • , Christoph Neumann-Haefelin
  • , Mark Douglas
  • , Sébastien Poulin
  • , Michel Bazinet
  • , R. Olga Metin
  • , Alessandro Vitale
    • Giovanni Battista Gaeta, Michael Schwarz, Souad Ben-Ali, Jose Ursic Bedoya, Barbara Testoni, Fabien Zoulim, Marie Laure Plissonnier, Massimo Levrero, Valerie Paradis, Sandrine Francois, Cecilia de Freitas, Furkan Kaysin, Laurence Lecomte, Christopher Morvan, Jocelyn Schramko, Kindness Bondezi, Marie Éve Baril, Ségolène Brichler, Athenaïs Gerber, Emmanuel Gordien, Vincent Mackiewicz, Harel Dahari, Valentina Svicher, Stéphane Chevaliez, Andrew Vaillant, Marc Bourliere

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program'. Together they form a unique fingerprint.
Sort by

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry

Biochemistry, Genetics and Molecular Biology